
|Videos|June 11, 2013
Raising Patient Cost Share for Specialty Medications
Debbie Stern, RPh, president of Rxperts, explains why a high entry cost for a specialty drug may dissuade a patient from filling and staying adherent to his or her prescription.
Advertisement
Debbie Stern, RPh, president of Rxperts, explains why a high entry cost for a specialty drug may dissuade a patient from filling and staying adherent to his or her prescription. Video from the 2013 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.
For more videos from this conference, vist our
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Poherdy, First Biosimilar to Perjeta, For HER2 Breast Cancer Indications
2
Ziftomenib Receives FDA Approval for Acute Myeloid Leukemia With NPM1 Mutations
3
The Dual Burden of CAR T-Cell Therapy: Financial and Time Toxicity in the Era of Precision Oncology
4
Study Finds Similar Outcomes Between hMPV and RSV Hospitalizations
5






















































































































































































































